Cargando…
Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis
Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and bloody diarrhea following treatment with ocrelizu...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Hellenic Society of Gastroenterology
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079880/ https://www.ncbi.nlm.nih.gov/pubmed/33948072 http://dx.doi.org/10.20524/aog.2021.0582 |